

**From:** [REDACTED]  
**Sent:** 23 March 2018 01:35  
**To:** response  
**Subject:** In support of HKEX consultation paper

Dear Sir or Madam,

Thank you for promulgating the new listing rules for biotech companies and reaching out for comments. I am supportive of this initiative which is absolutely the right thing to do. The consolidated comments submitted by the BayHelix Group reflects my view as a member.

I also hope that such reach-out can be a more regular process as the nature of biotech business and regulatory environment evolve quite rapidly and quite heterogeneous (e.g., from cosmetics to drugs, from biofuel to medical devices). Continued monitoring and understanding the market place are likely important for HKEX to stay ahead of competing exchanges and be the preferred destination for listing. Thank you for your kind attention.

Best regards,  
Lance Wong, Ph.D.  
Managing Director, Strand Bio  
San Mateo, California  
U.S.A  
[REDACTED]

The contents of this e-mail, and any attachments, are confidential and are provided for the exclusive use of the intended recipients. If you are not an intended recipient and have received this e-mail in error please do not read, use, copy, print or disclose the email or its attachments. Instead, please notify the sender immediately by return e-mail and then delete the message and any attachments from your system.